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flowmetry: the effect of angiotensin II
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Summary Many colorectal liver metastases are hypovascular, and their low level of perfusion is associated
with limited drug uptake and poor response rates with regional chemotherapy. We have previously shown that
hepatic arterial vasoconstrictors may increase drug delivery to liver tumours, but the underlying
haemodynamic changes have not been defined. Using intraoperative laser Doppler flowmetry (LDF) we have
assessed the effect of intraarterial angiotensin II (Al) on tumour blood flow in ten patients with colorectal liver
metastases.
Measurements were performed during placement of infusion catheters for regional chemotherapy. Blood
flow was recorded continuously with a Periflux PF3 perfusion monitor via a probe held on the tumour surface,
following hepatic arterial infusion of 15 ltg AII over 90s.
Six patients with isolated small metastases (<5 cm in diameter) showed increases in flow, which reached a
peak at 170-240 s from the start of All infusion, and which were closely correlated with the corresponding
increase in arterial pressure (r = 0.92, P = 0.009). Of the four patients with large confluent tumour deposits,
two showed smaller transient increases in flow over the first 60 s of AII infusion and two had no measurable
flow response.
Increased blood flow following All infusion may increase the exposure of tumour to therapeutic agents.
This study suggests that both tumour size and the effect upon systemic arterial pressure may be important
determinants of the blood flow response to AII. LDF may provide useful information about the potential of
All and other vasoconstrictors to enhance targeting precision.
Regional administration of chemotherapeutic agents provides
a means of increasing drug delivery to liver metastases
(Kemeny et al., 1987), which derive their blood supply almost
entirely from the hepatic artery (Ackerman et al., 1969). It
has been suggested that the use of vasoconstrictors would
further increase tumour exposure to regionally-delivered
drugs (Suzuki et al., 1981). On the grounds that tumour
blood vessels are deficient in both smooth muscle and
adrenergic receptors, and are believed to lack the capacity to
respond normally to vasoactive agents (Mattsson et al.,
1977). Selective constriction of vessels supplying normal liver
would be expected to divert a higher proportion of hepatic
arterial flow, together with any arterially-infused drug to
tumour. We have previously demonstrated that angiotensin
II increases delivery of a regionally administered marker to
liver tumour (Hemingway et al., 1991), and increases tumour
uptake of radiolabelled albumen microspheres in patients
with colorectal liver metastases (Goldberg et al., 1991). How-
ever, the haemodynamic changes underlying these results
have not been fully defined. Sasaki et al. (1985) reported that
angiotensin II increased the concentration of arterially -
infused krypton - 81 m in both primary and metastatic liver
tumours. This implies an increase in tumour blood flow
relative to total hepatic arterial flow, but, as angiotensin II
reduces hepatic arterial flow in the normal liver (Richardson
& Witherington, 1976), the question of whether tumour
blood flow is increased in absolute terms remains open.
Methods
Laser Doppler flowmetry (LDF) exploits the Doppler shift in
backscattered laser light to measure capillary blood flow in
the region of a flow probe tip in contact with tissue. We have
used LDF to determine the effects of regionally-administered
angiotensin II on tumour blood flow in ten patients with
biopsy-proven colorectal liver metastases. Four patients had
widespread confluent liver tumour deposits and the
remainder had single or multiple isolated tumours of up to
5 cm in diameter.
All patients were studied at the time of placement of
infusion catheters for regional delivery of chemotherapeutic
drug to liver tumour. This study was approved by the hos-
pital ethical committee, and all patients gave informed con-
sent.
The gastroduodenal artery was identified at laparotomy,
tied distally and cannulated with a silastic tube connected to
a subcutaneous injection port. The tip of the cannula was
positioned at the junction of the gastroduodenal artery and
the hepatic artery.
A fibre-optic probe attached to a laser Doppler flowmeter
(Periflux PF3, Perimed, UK) was held manually on the sur-
face of an accessible tumour, using a plastic holder which
reduced contact pressure on the measurement area and
restricted angular movement of the probe. Care was taken to
apply the minimal pressure necessary to maintain contact
with the tissue and to avoid movement of the probe during
the course of the measurements. The bandwidth setting of
the Doppler signal processor was 12 KHz, and the output
signal, representing tissue perfusion in arbitrary 'perfusion
units' was recorded with a 3 s time constant on a chart
recorder.
When a steady blood flow reading had been obtained for
at least 1 min, 15 ,g of angiotensin II dissolved in 3 ml of
physiological saline was infused over 90 s into the hepatic
artery catheter, which was then flushed with 5 ml saline.
Blood flow recording continued for a period of between 5
and 9 min after the start of the AII infusion. Systemic
arterial pressure was measured continuously with an
automatic sphygmomanometer.
Results
The effects of angiotensin II on tumour blood flow are
summarised in Table I. Flow increased in eight of the ten
patients, but there were striking qualitative and quantitative
differences in the blood flow response between patients with
isolated small metastases and those with large tumour
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Table I Effect of angiotensin II on tumour blood flow
Tumour size Tumour bloodflow (PU) Time to
Patient (cm) Baseline Peak Ratio peak (s)
1 2 33 130 3.9 170
2 2 26 138 5.3 190
3 2 30 300 10.0 240
4 2 26 40 1.5 130
5 3 30 36 1.2 180
6 5 10 13 1.3 240
7 c 20 38 1.9 30
8 c 45 125 2.8 30
9 c 16 16 1.0 -
10 c 32 3 21.0 -
PU, perfusion units; C, large, confluent tumour.
deposits. In the former group, perfusion increased to a peak
of up to ten times its baseline level over a period 130-240 s
from the start of the All infusion, and then returned to
baseline over a similar period (Figure 1, upper curve). Of the
four patients with large tumours, two showed no blood flow
response to AII infusion, two showed a relatively low and
short-lived peak which occurred only 30 s after the start of
the angiotensin II infusion (Figure 1, lower curve).
Systolic pressure rose from a mean baseline of 116 mmHg
(s.d. 20) to a peak of 143 mmHg (s.d. 27) over a period of
130-240 s from the start of angiotensin II infusion, and then
decline to baseline over value or lower over a similar period
of time. The respective time courses of changes in arterial
pressure and blood flow in small tumours were thus approx-
imately parallel.
There was a significant correlation between the relative
increase in perfusion in the six isolated small (5 cm or less)
tumours studied and the synchronous relative increase in
blood pressure (r = 0.92, P = 0.009) (Figure 2).
Discussion
Although LDF does not provide flow values in absolute
volume units, it is accepted as a reliable indicator of relative
flow changes. In the present study, tumour blood flow was
measured relative to its pre-angiotensin baseline, rather than
the variable level of flow in normal liver tissue. The results
suggest that regional angiotensin II infusion produces an
increase in the absolute level of tumour blood flow in most
cases, and that tumour size may be an important determinant
of the precise characteristics of the blood flow response.
The fact that the change in blood flow to small tumours
paralleled the change in arterial pressure with respect to time
is consistent with the suggestion that variations in tumour
flow are in part related to an absence of autoregulatory
mechanisms (Suzuki et al., 1981). The close correlation
between the magnitude of the peak changes in flow and
pressure further supports this concept. However, the fact that
the flow change was several fold larger than the pressure
change implies a significant reduction in tumour vascular
resistance, at least in the superficial region accessible to
measurement by this technique. It is possible that blood
vessels within the tumour are occluded by high interstitial
pressure under baseline conditions (Ackerman et al., 1988),
but open under the increased perfusion pressure following
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Figure 1 Perfusion curves after infusion of angiotensin II in a
small hepatic tumour (upper curve) and a large confluent hepatic
tumour (lower perfusion curve).
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Figure 2 Correlation between peak systolic arterial pressure and
the pre-infusion:post-infusion flow ratio after infusion of
anagiotensin II.
angiotensin II administration.
Many liver tumours are hypovascular, and their relatively
low level of perfusion is associated with limited uptake of
regionally administered chemotherapeutic drugs (Sigurdson
et al., 1986). Indeed, patients with hypovascular colorectal
liver metastases have been shown to have poor response rates
with regional chemotherapy (Daly et al., 1985). Increased
tumour blood flow following angiotensin II infusion may
increase the exposure of tumour to chemotherapeutic agents,
and LDF may provide useful information about the potential
of All and other vasoconstrictors to enhance targeting
precision. Many other factors may also contribute to the
therapeutic effect of cytotoxic agents. For example, we have
shown that the intrahepatic distribution of regionally-
delivered microspheres in a rat liver tumour model is
influenced by the physical characteristics of the particulate
suspension (Anderson et al., 1991). In addition, any effect of
angiotensin II on cellular uptake of drugs could modify the
consequences of flow manipulation. However, assuming that
blood flow remains a significant determinant ofdrug delivery
to tumour, measurement of the blood flow response by LDF
may provide an index of the potential benefit of vasconstric-
tor targeting.
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